3 weeks ago

Watching cancer cells live could transform drug discovery

Watching cancer cells live could transform drug discovery
Watching cancer cells live could transform drug discovery · thehansindia.com

Scientists often study cells only after they have been dyed, frozen, or broken apart, when the cells are no longer living.

A new platform lets researchers watch living cells continuously, without harming them.

By watching cells stay alive, scientists can see how medicines change cells in real time.

This could help find new cancer medicines faster, because most cancer drug candidates fail before they reach patients.

Experts say many of those failures happen because laboratory models don't show how living cells really behave.

The same technology could also help study brain diseases, rare diseases, the immune system, and healing.

In India, about 1.4 million new cancer cases were estimated in 2022, so better research tools are needed.

Researchers hope that watching living cells will reveal new insights that were impossible to see before.

Key facts

Platform
Real-time living cell observation platform run by Precigenetics
Company HQ
San Francisco, USA
Key advocates
Dr. Shyam Aggarwal (Sir Ganga Ram Hospital) and Parmita Mishra (Precigenetics CEO)
Potential applications
Cancer research, precision medicine, immunology, neuroscience, rare diseases, regenerative medicine
India cancer cases (2022)
Estimated 1.4 million new cases (IARC data)
Cancer burden projection
ICMR projects India's cancer burden will rise over the coming decade
Current model limitation
Most oncology drug candidates fail in clinical development; lab models rely on end-point measurements and can miss living cells' dynamic behaviour

Quotes

Dr. Shyam Aggarwal

Chairperson, Department of Medical Oncology, Sir Ganga Ram Hospital

“Unlike conventional laboratory techniques that often require cells to be stained, fixed or broken apart before analysis, the platform seeks to monitor living biology continuously, allowing scientists to study cellular behaviour over time rather than relying on isolated end-point measurements.”
thehansindia.com
“Understanding precision oncology with comprehensive genome profiling (CGP) and minimal residual disease detection (MRD) will help physicians improve targeted personalised medicine for cancer patients.”
thehansindia.com

Sources

Related news